NO20082679L - Sammensetning og fremgangsmate for a behandle CNS lidelser - Google Patents

Sammensetning og fremgangsmate for a behandle CNS lidelser

Info

Publication number
NO20082679L
NO20082679L NO20082679A NO20082679A NO20082679L NO 20082679 L NO20082679 L NO 20082679L NO 20082679 A NO20082679 A NO 20082679A NO 20082679 A NO20082679 A NO 20082679A NO 20082679 L NO20082679 L NO 20082679L
Authority
NO
Norway
Prior art keywords
composition
cns disorders
treating cns
treatment
thienopyridinone
Prior art date
Application number
NO20082679A
Other languages
English (en)
Norwegian (no)
Inventor
Dongli Chen
Oren Becker
Silvia Noiman
Yael Marantz
Alexander Heifetz
Pradyumna Mohanty
Boaz Inbal
Shay Bar-Haim
Mercedes Lobera
Laurence Wu
Sharon Shacham
Dale S Dhanoa
Original Assignee
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharm Inc filed Critical Epix Pharm Inc
Publication of NO20082679L publication Critical patent/NO20082679L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20082679A 2005-11-10 2008-06-10 Sammensetning og fremgangsmate for a behandle CNS lidelser NO20082679L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/271,019 US7598265B2 (en) 2004-09-30 2005-11-10 Compositions and methods for treating CNS disorders
PCT/US2006/043140 WO2007058805A2 (fr) 2005-11-10 2006-11-06 Compositions et procedes destines au traitement des troubles du snc

Publications (1)

Publication Number Publication Date
NO20082679L true NO20082679L (no) 2008-06-10

Family

ID=37946751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082679A NO20082679L (no) 2005-11-10 2008-06-10 Sammensetning og fremgangsmate for a behandle CNS lidelser

Country Status (17)

Country Link
US (2) US7598265B2 (fr)
EP (1) EP1959954A2 (fr)
JP (1) JP2009515877A (fr)
KR (1) KR20080067001A (fr)
CN (1) CN101340908A (fr)
AR (1) AR057887A1 (fr)
AU (1) AU2006315854A1 (fr)
BR (1) BRPI0618493A2 (fr)
CA (1) CA2629312C (fr)
CR (1) CR10062A (fr)
EA (1) EA200801302A1 (fr)
IL (1) IL191168A0 (fr)
MA (1) MA30037B1 (fr)
NO (1) NO20082679L (fr)
TW (1) TW200735868A (fr)
WO (1) WO2007058805A2 (fr)
ZA (1) ZA200804951B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
GB0526258D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2445877B1 (fr) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Composés bicycliques et leurs procédés de fabrication et d'utilisation
BRPI1013777A8 (pt) * 2009-04-13 2017-09-19 Theravance Biopharma R&D Ip Llc Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
US20230139125A1 (en) * 2021-02-04 2023-05-04 Richard Natrillo Dietary supplement for improving brain performance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE4023270A1 (de) * 1990-07-21 1992-02-06 Hoechst Ag Hydrophile mischpolymere sowie deren verwendung in der reprographie
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
US6979309B2 (en) * 1997-02-14 2005-12-27 Nxstage Medical Inc. Systems and methods for performing blood processing and/or fluid exchange procedures
DE19724980A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
DE69839887D1 (de) 1997-10-02 2008-09-25 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
WO1999043681A1 (fr) 1998-02-26 1999-09-02 Neurogen Corporation Pyridines heteroaryle fondues substituees 4-(4-piperidylmethylamino); ligands du recepteur cerebral gaba
DE19815026A1 (de) 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1999051932A2 (fr) * 1998-04-08 1999-10-14 Moshier Gary S Systeme, sous-systemes et composants pour la neutralisation de mines enterrees au moyen de munitions lancees
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1173168A2 (fr) 1999-04-28 2002-01-23 Respiratorius AB Un compose pour l'utilisation d'un medicament destine au traitement de troubles de contraction bronchique
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CA2386163A1 (fr) 1999-10-01 2001-04-12 Masanori Tobe Nouveaux derives de quinazoline
EP1270568A1 (fr) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-Méthyl-4-(3-éthoxy-9H-thioxanthène-ylidène)-pipéridine et son utilasition en tant qu'antagoniste du recepteur 5-HT2B et/ou H1
WO2003020728A1 (fr) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company Agents antiviraux a base de 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
WO2004017950A2 (fr) 2002-08-22 2004-03-04 Piramed Limited Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux
AU2003277215A1 (en) 2002-10-01 2004-04-23 Predix Pharmaceuticals Holdings, Inc. Novel neurokinin antagonists and methods of use thereof
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
NZ542236A (en) 2003-03-31 2008-05-30 Predix Pharmaceuticals Holding New piperidinylamino-thieno[2,3-d]pyrimidine compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
KR100764330B1 (ko) 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한mGluR2 길항제 및 AChE 억제제의 조합물
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005049027A2 (fr) 2003-11-03 2005-06-02 Probiodrug Ag Combinaisons utiles au traitement de troubles neuronaux
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
WO2008045558A2 (fr) 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de benzothiadazine et leur utilisation
ES2589907T3 (es) 2006-11-17 2016-11-17 Microdose Therapeutx, Inc. Análogos de 5-polifosfato de ribosa sustituido en 1' y su uso como moduladores de la actividad de receptores P2Y

Also Published As

Publication number Publication date
CN101340908A (zh) 2009-01-07
AR057887A1 (es) 2007-12-26
CR10062A (es) 2009-05-14
WO2007058805A3 (fr) 2007-10-04
MA30037B1 (fr) 2008-12-01
BRPI0618493A2 (pt) 2011-08-30
US20060234998A1 (en) 2006-10-19
ZA200804951B (en) 2009-04-29
CA2629312A1 (fr) 2007-05-24
CA2629312C (fr) 2014-08-12
JP2009515877A (ja) 2009-04-16
KR20080067001A (ko) 2008-07-17
WO2007058805A2 (fr) 2007-05-24
TW200735868A (en) 2007-10-01
EP1959954A2 (fr) 2008-08-27
US7598265B2 (en) 2009-10-06
IL191168A0 (en) 2008-12-29
EA200801302A1 (ru) 2009-02-27
AU2006315854A1 (en) 2007-05-24
US20110195953A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
DE602007008524D1 (de) Spiroimidazol-derivate als ppar-modulatoren
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
TW200602330A (en) Compounds and compositions as PPAR modulators
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20063137L (no) Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom
TW200735868A (en) Compositions and methods for treating CNS disorders
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application